Please enable JavaScript to continue using this application.

Compare $TNGX vs $TVTX | Chartloom

Compare

$TNGX vs $TVTX

Tango Therapeutics Inc · Travere Therapeutics Inc

TNGX

Tango Therapeutics Inc

TVTX

Travere Therapeutics Inc

Compare $TNGX vs $TVTX

Comparing Tango Therapeutics Inc and Travere Therapeutics Inc

TNGXTango Therapeutics Inc

TVTXTravere Therapeutics Inc

TNGXTango Therapeutics Inc

Market cap

$3.87B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

121.5%

YTD performance

166.6%

52W performance

244.6%

FCF yield

-3.7%

TVTXTravere Therapeutics Inc

Market cap

$4.85B

P/E (TTM)

—

Forward P/E (NTM)

30.06x

Forward P/S (NTM)

5.04x

Rev growth (TTM)

77.1%

YTD performance

31.9%

52W performance

99.0%

FCF yield

0.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

TNGX

TVTX

Detailed metrics comparison

TNGX

Tango Therapeutics Inc

TVTX

Travere Therapeutics Inc

Market Cap

TNGX$3.87B

TVTX$4.85B

Enterprise Value

TNGX$3.52B

TVTX$5.33B

Price

TNGX$23.81

TVTX$52.13

P/E Ratio

TNGXN/A

TVTXN/A

P/S Ratio

TNGX71.83x

TVTX8.20x

EV/Sales

TNGX65.41x

TVTX9.02x

EV/EBITDA

TNGX0.00x

TVTX216.50x

P/B Ratio

TNGX3.82x

TVTX218.84x

P/FCF Ratio

TNGXN/A

TVTX314.77x

EV/FCF

TNGX-24.40x

TVTX346.27x

PEG Ratio

TNGXN/A

TVTXN/A

Forward P/E (NTM)

TNGXN/A

TVTX30.06x

Forward P/S (NTM)

TNGXN/A

TVTX5.04x

Revenue (TTM)

TNGX$54M

TVTX$591M

Revenue Growth (YoY)

TNGX121.5%

TVTX77.1%

Forward Rev Growth

TNGX732.8%

TVTX49.4%

Gross Margin (TTM)

TNGX0.0%

TVTX98.6%

Operating Margin (TTM)

TNGX0.0%

TVTX0.0%

EBITDA Margin (TTM)

TNGX-249.8%

TVTX3.9%

Net Margin (TTM)

TNGX-229.9%

TVTX-7.4%

FCF Margin (TTM)

TNGX-268.1%

TVTX2.6%

Net Income (TTM)

TNGX$-124M

TVTX$-43M

FCF (TTM)

TNGX$-144M

TVTX$15M

EPS (TTM)

TNGX-$0.83

TVTX-$0.46

ROE (TTM)

TNGX-2574.0%

TVTX-5579.0%

ROA (TTM)

TNGX-2336.0%

TVTX-696.0%

ROIC (TTM)

TNGX-2574.0%

TVTX-940.0%

Cash

TNGX$346M

TVTX$118M

Debt

TNGX$0

TVTX$603M

Net Cash/Debt

TNGX$346M

TVTX$-485M

Current Ratio (TTM)

TNGX50.82x

TVTX4.05x

Quick Ratio (TTM)

TNGX49.95x

TVTX3.75x

Debt/Equity (TTM)

TNGX0.00x

TVTX24.58x

Debt/Assets (TTM)

TNGX0.0%

TVTX0.0%

Interest Coverage (TTM)

TNGXN/A

TVTXN/A

Net Debt/EBITDA (TTM)

TNGX0.00x

TVTX0.00x

Beta

TNGX1.18

TVTX1.08

52W Performance

TNGX244.6%

TVTX99.0%

YTD Performance

TNGX166.6%

TVTX31.9%

% from 52W High

TNGX-30.8%

TVTX-24.2%

% from 52W Low

TNGX255.9%

TVTX130.7%

Asset Turnover (TTM)

TNGX0.26x

TVTX0.95x

FCF Yield (TTM)

TNGX-3.7%

TVTX0.3%

Earnings Yield (TTM)

TNGX-3.2%

TVTX-0.9%

Dividend Yield (TTM)

TNGXN/A

TVTXN/A

Rule of 40

TNGX-146.6

TVTX79.7

EV/GP/RG

TNGXN/A

TVTX0.14

Ticker research

View TNGX research View TVTX research

Metric	TNGX Tango Therapeutics Inc	TVTX Travere Therapeutics Inc
Market & Valuation
Market Cap	$3.87B	$4.85B
Enterprise Value	$3.52B	$5.33B
Price	$23.81	$52.13
P/E Ratio	N/A	N/A
P/S Ratio	71.83x	8.20x
EV/Sales	65.41x	9.02x
EV/EBITDA	0.00x	216.50x
P/B Ratio	3.82x	218.84x
P/FCF Ratio	N/A	314.77x
EV/FCF	-24.40x	346.27x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	30.06x
Forward P/S (NTM)	N/A	5.04x
Revenue & Growth
Revenue (TTM)	$54M	$591M
Revenue Growth (YoY)	121.5%	77.1%
Forward Rev Growth	732.8%	49.4%
Profitability
Gross Margin (TTM)	0.0%	98.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-249.8%	3.9%
Net Margin (TTM)	-229.9%	-7.4%
FCF Margin (TTM)	-268.1%	2.6%
Net Income (TTM)	$-124M	$-43M
FCF (TTM)	$-144M	$15M
EPS (TTM)	-$0.83	-$0.46
ROE (TTM)	-2574.0%	-5579.0%
ROA (TTM)	-2336.0%	-696.0%
ROIC (TTM)	-2574.0%	-940.0%
Financial Health
Cash	$346M	$118M
Debt	$0	$603M
Net Cash/Debt	$346M	$-485M
Current Ratio (TTM)	50.82x	4.05x
Quick Ratio (TTM)	49.95x	3.75x
Debt/Equity (TTM)	0.00x	24.58x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.18	1.08
52W Performance	244.6%	99.0%
YTD Performance	166.6%	31.9%
% from 52W High	-30.8%	-24.2%
% from 52W Low	255.9%	130.7%
Efficiency & Yields
Asset Turnover (TTM)	0.26x	0.95x
FCF Yield (TTM)	-3.7%	0.3%
Earnings Yield (TTM)	-3.2%	-0.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-146.6	79.7
EV/GP/RG	N/A	0.14
Ticker research	View TNGX research	View TVTX research

Valuation

P/S Ratio

TVTX

8.20x

TNGX

71.83x

EV/FCF

TNGX

-24.40x

TVTX

346.27x

Growth & revenue

Revenue Growth TTM

TNGX

121.5%

TVTX

77.1%

Forward Revenue Growth

TNGX

732.8%

TVTX

49.4%

Profitability & performance

Gross Margin

TVTX

98.6%

TNGX

0.0%

ROE

TNGX

-2574.0%

TVTX

-5579.0%

FCF Yield %

TVTX

0.3%

TNGX

-3.7%

52-Week Performance

TNGX

244.6%

TVTX

99.0%

Detailed metrics comparison

TNGX

Tango Therapeutics Inc

TVTX

Travere Therapeutics Inc

Market Cap

TNGX$3.87B

TVTX$4.85B

Enterprise Value

TNGX$3.52B

TVTX$5.33B

Price

TNGX$23.81

TVTX$52.13

P/E Ratio

TNGXN/A

TVTXN/A

P/S Ratio

TNGX71.83x

TVTX8.20x

EV/Sales

TNGX65.41x

TVTX9.02x

EV/EBITDA

TNGX0.00x

TVTX216.50x

P/B Ratio

TNGX3.82x

TVTX218.84x

P/FCF Ratio

TNGXN/A

TVTX314.77x

EV/FCF

TNGX-24.40x

TVTX346.27x

PEG Ratio

TNGXN/A

TVTXN/A

Forward P/E (NTM)

TNGXN/A

TVTX30.06x

Forward P/S (NTM)

TNGXN/A

TVTX5.04x

Revenue (TTM)

TNGX$54M

TVTX$591M

Revenue Growth (YoY)

TNGX121.5%

TVTX77.1%

Forward Rev Growth

TNGX732.8%

TVTX49.4%

Gross Margin (TTM)

TNGX0.0%

TVTX98.6%

Operating Margin (TTM)

TNGX0.0%

TVTX0.0%

EBITDA Margin (TTM)

TNGX-249.8%

TVTX3.9%

Net Margin (TTM)

TNGX-229.9%

TVTX-7.4%

FCF Margin (TTM)

TNGX-268.1%

TVTX2.6%

Net Income (TTM)

TNGX$-124M

TVTX$-43M

FCF (TTM)

TNGX$-144M

TVTX$15M

EPS (TTM)

TNGX-$0.83

TVTX-$0.46

ROE (TTM)

TNGX-2574.0%

TVTX-5579.0%

ROA (TTM)

TNGX-2336.0%

TVTX-696.0%

ROIC (TTM)

TNGX-2574.0%

TVTX-940.0%

Cash

TNGX$346M

TVTX$118M

Debt

TNGX$0

TVTX$603M

Net Cash/Debt

TNGX$346M

TVTX$-485M

Current Ratio (TTM)

TNGX50.82x

TVTX4.05x

Quick Ratio (TTM)

TNGX49.95x

TVTX3.75x

Debt/Equity (TTM)

TNGX0.00x

TVTX24.58x

Debt/Assets (TTM)

TNGX0.0%

TVTX0.0%

Interest Coverage (TTM)

TNGXN/A

TVTXN/A

Net Debt/EBITDA (TTM)

TNGX0.00x

TVTX0.00x

Beta

TNGX1.18

TVTX1.08

52W Performance

TNGX244.6%

TVTX99.0%

YTD Performance

TNGX166.6%

TVTX31.9%

% from 52W High

TNGX-30.8%

TVTX-24.2%

% from 52W Low

TNGX255.9%

TVTX130.7%

Asset Turnover (TTM)

TNGX0.26x

TVTX0.95x

FCF Yield (TTM)

TNGX-3.7%

TVTX0.3%

Earnings Yield (TTM)

TNGX-3.2%

TVTX-0.9%

Dividend Yield (TTM)

TNGXN/A

TVTXN/A

Rule of 40

TNGX-146.6

TVTX79.7

EV/GP/RG

TNGXN/A

TVTX0.14

Ticker research

View TNGX research View TVTX research

Metric	TNGX Tango Therapeutics Inc	TVTX Travere Therapeutics Inc
Market & Valuation
Market Cap	$3.87B	$4.85B
Enterprise Value	$3.52B	$5.33B
Price	$23.81	$52.13
P/E Ratio	N/A	N/A
P/S Ratio	71.83x	8.20x
EV/Sales	65.41x	9.02x
EV/EBITDA	0.00x	216.50x
P/B Ratio	3.82x	218.84x
P/FCF Ratio	N/A	314.77x
EV/FCF	-24.40x	346.27x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	30.06x
Forward P/S (NTM)	N/A	5.04x
Revenue & Growth
Revenue (TTM)	$54M	$591M
Revenue Growth (YoY)	121.5%	77.1%
Forward Rev Growth	732.8%	49.4%
Profitability
Gross Margin (TTM)	0.0%	98.6%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-249.8%	3.9%
Net Margin (TTM)	-229.9%	-7.4%
FCF Margin (TTM)	-268.1%	2.6%
Net Income (TTM)	$-124M	$-43M
FCF (TTM)	$-144M	$15M
EPS (TTM)	-$0.83	-$0.46
ROE (TTM)	-2574.0%	-5579.0%
ROA (TTM)	-2336.0%	-696.0%
ROIC (TTM)	-2574.0%	-940.0%
Financial Health
Cash	$346M	$118M
Debt	$0	$603M
Net Cash/Debt	$346M	$-485M
Current Ratio (TTM)	50.82x	4.05x
Quick Ratio (TTM)	49.95x	3.75x
Debt/Equity (TTM)	0.00x	24.58x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.18	1.08
52W Performance	244.6%	99.0%
YTD Performance	166.6%	31.9%
% from 52W High	-30.8%	-24.2%
% from 52W Low	255.9%	130.7%
Efficiency & Yields
Asset Turnover (TTM)	0.26x	0.95x
FCF Yield (TTM)	-3.7%	0.3%
Earnings Yield (TTM)	-3.2%	-0.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-146.6	79.7
EV/GP/RG	N/A	0.14
Ticker research	View TNGX research	View TVTX research